These Cryptocurrencies Have Become Wall Street Favorites and Deserve a Place in Your Portfolio
Key PointsOf the top 20 spot crypto ETFs, 12 are dedicated to Bitcoin and six to Ethereum.
Nasdaq News
DAX Climbs Higher On Tech Strength
(RTTNews) - German stocks gained modest ground in positive territory Tuesday morning even as the mood remained cautious amid elevated oil prices and higher bond yields.
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation
Key PointsBristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still trades at a discounted valuation.
Binance Just Invested $100 Million in Circle Internet Group. Here's What It Really Means
Key PointsThe Binance investment is really about distribution.
Biotech Stocks Facing FDA Decision In October 2026
(RTTNews) - The FDA's October decision calendar looks relatively light, with only a limited number of PDUFA dates scheduled.
The Stock Market Sounds an Alarm After Warren Buffett Issues a Warning. History Says This Will Happen Next.
Key PointsIn May, Warren Buffett warned that many investors were treating the stock market like a casino.
Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma
(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company, announced updated Phase 1 clinical data for IBI3003 in patients with relapsed or refractory multiple myeloma (R/R MM), presented orally at the 23rd International Myeloma Society (IMS) Annual Meeting 2026
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
Key PointsVertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance.
Not Broadcom. Not AMD. Nvidia's Biggest Threat Continues to Be Something Near and Dear to Its Heart.
Key PointsNvidia, Broadcom, and Advanced Micro Devices (AMD) have taken full advantage of otherworldly enterprise spending on AI-accelerating chips.
The Stock Market Is Repeating a Pattern Seen Only Once in the Past 100 Years. Here's What History Says Comes Next.
Key PointsStocks are soaring, but that also means we could be entering bubble territory.
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
Key PointsCRISPR Therapeutics has two important data readouts coming up soon.
If You Invest $500 a Month in This High-Yield Dividend Stock, Here's the Dividend Income It Could Produce Over 10 Years (Spoiler: It's More Than $23,000)
Key PointsVerizon's dividend yield is very generous.
Advanced Micro Devices (AMD) Just Joined the $1 Trillion Club. Next Stop: $2 Trillion?
Key PointsAdvanced Micro Devices (AMD) recently became the latest American public company to amass a $1 trillion valuation, joining 12 others.
Will President Trump Crash the Stock Market? History Says This Could Come Next.
Key PointsAlthough the stock market has performed well in 2026, rising inflation and higher interest rates could derail the rally.
Why a Bigger 2027 Social Security COLA Might Still Feel Like a Pay Cut for Millions of Retirees
Key PointsCurrent estimates say 2027's Social Security COLA will be larger than this year's 2.8% increase.
Lilly's Foundayo Tops Oral Semaglutide In New Diabetes Analysis
(RTTNews) - Eli Lilly and Company (LLY) reported that Foundayo 17.2 mg was associated with greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes, based on a new indirect treatment comparison.
Micron Earned More in 3 Months Than Tesla Did in 3 Years. Prediction: It Will Be Worth More Than Tesla Before 2028.
Key PointsMicron earned $28.2 billion in GAAP net income in its fiscal third quarter, which ended May 28.
The Odds of the Fed Ramping Up Its Rate-Hiking Cycle Are Skyrocketing, and 4 Variables -- 2 Directly Tied to President Donald Trump -- Are to Blame
Key PointsThe FOMC kicked off only the fourth rate-hiking cycle of the 21st century on Sept. 16 to combat persistently elevated inflation.
Not the GPUs. This Overlooked Piece of Nvidia's Business Could Matter Most for the Stock's Next Leg Up.
Key PointsNvidia has seen revenue soar in the triple digits thanks to its strength in the GPU market.
Lilly's Foundayo Outperforms Oral Semaglutide In New Diabetes Analysis
(RTTNews) - Tuesday, Eli Lilly (LLY) said Foundayo 17.2 mg showed greater weight loss and A1C reductions than oral semaglutide 25 mg in an indirect treatment comparison involving adults with type 2 diabetes.
This feed is responsible for generating the rss feed related to the topic latest article
Subscribe to Nasdaq News feed